← Tillbaka till ranking

Target Corporation

TGT SP500 Consumer Staples
AVVAKTA
55/100
Rank 98 av 500
156.00 USD -0.45% idag Live

Kursutveckling (180 dagar)

TGT OMX30 (normaliserad)

Kursutveckling vs OMX30

1 dag
-0.45%
-1.5% vs OMX30
1 vecka
-0.92%
+0.1% vs OMX30
1 månad
-4.73%
-5.2% vs OMX30
3 månader
+20.65%
+20.2% vs OMX30
6 månader
+32.42%
+18.6% vs OMX30

Fundamentala nyckeltal

16.2
16.3
2.14
4.0
0.7
9.9
+100.5%
+5.3%
4.1%
6.0%
26.4%
5.7%
108%
0.99
3.0%
70.9B
BUY Riktkurs: 165 USD (34 analytiker)

AI-analys

15.0
0.0
55.2
MEDEL

Kort sikt (3 månader)

56/100

Baserat enbart på tekniska signaler.

Lång sikt (3 år)

53/100

Baserat enbart på sentiment, inga fundamenta tillgängliga.

Fallback: teknisk=15, sentiment=0. AI-analys ej tillgänglig.

  • AI-analys misslyckades

Senaste nyheter

bbc_business Sat, 26 Se
Heathrow Airport warns third runway could be delayed by four years

The UK's busiest airport cautions it may miss the government target of 2035 as ministers say the deadline has "always been ambitious".

yahoo_finance 2026-06-27
Here’s What the Street Thinks About Eli Lilly and Company (LLY)

Eli Lilly and Company (NYSE:LLY) is one of the safe stocks for beginners to buy in 2026. Eli Lilly and Company (NYSE:LLY) received a rating update from Leerink on June 25. The firm lifted the price ta...

yahoo_finance 2026-06-27
Here’s What the Street Thinks About Eli Lilly and Company (LLY)

Eli Lilly and Company (NYSE:LLY) is one of the safe stocks for beginners to buy in 2026. Eli Lilly and Company (NYSE:LLY) received a rating update from Leerink on June 25. The firm lifted the price ta...

yahoo_finance 2026-06-27
Here’s What the Street Thinks About Eli Lilly and Company (LLY)

Eli Lilly and Company (NYSE:LLY) is one of the safe stocks for beginners to buy in 2026. Eli Lilly and Company (NYSE:LLY) received a rating update from Leerink on June 25. The firm lifted the price ta...

yahoo_finance 2026-06-25
The Bull Case For Eli Lilly (LLY) Could Change Following New Multi‑Target R&D Alliances With Biotechs

In recent days, Abbisko Therapeutics and BioArctic each announced new research and license agreements with Eli Lilly, adding multi-target discovery work worth up to about US$1.90 billion in milestones...

yahoo_finance 2026-06-25
The Bull Case For Eli Lilly (LLY) Could Change Following New Multi‑Target R&D Alliances With Biotechs

In recent days, Abbisko Therapeutics and BioArctic each announced new research and license agreements with Eli Lilly, adding multi-target discovery work worth up to about US$1.90 billion in milestones...

yahoo_finance 2026-06-25
The Bull Case For Eli Lilly (LLY) Could Change Following New Multi‑Target R&D Alliances With Biotechs

In recent days, Abbisko Therapeutics and BioArctic each announced new research and license agreements with Eli Lilly, adding multi-target discovery work worth up to about US$1.90 billion in milestones...